Open Access. Powered by Scholars. Published by Universities.®

Education Commons™

Open Access. Powered by Scholars. Published by Universities.®

University of St Augustine for Health Sciences

Theses/Dissertations

2023

SGLT2i use for diabetic nephropathy

Articles 1 - 1 of 1

Full-Text Articles in Education

Expanding Use Of Sodium-Glucose Cotransporter-2 Inhibitor (Sglt2i) In Managing Patients With Diabetes And Chronic Kidney Disease In Primary Care, Stephanie Wu Oct 2023

Expanding Use Of Sodium-Glucose Cotransporter-2 Inhibitor (Sglt2i) In Managing Patients With Diabetes And Chronic Kidney Disease In Primary Care, Stephanie Wu

Student Scholarly Projects

Practice Problem: In 2022, the addendum of standards of medical care in diabetes management was annotated to recommend the broader use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) to treat patients with Type 2 diabetes mellitus (DM) and diabetic nephropathy. Despite the Department of Veterans Affairs’ (VA) efforts to include SLGT2i as a formulary, non-restrictive prescription in the primary care ordering menu, the overall utilization rates of SGLT2i remained relatively low in primary care.

PICOT: The PICOT question that guided this project was: In patients with DM and chronic kidney disease (CKD) (P), how does an evidence-based guideline algorithm bundle (I) …

Go to article